Eyegate Pharmaceuticals Stock Price, News & Analysis (NASDAQ:EYEG)

$1.26 -0.04 (-3.08 %)
(As of 01/16/2018 04:42 AM ET)
Previous Close$1.30
Today's Range$1.24 - $1.34
52-Week Range$0.90 - $3.90
Volume291,400 shs
Average Volume378,267 shs
Market Capitalization$21.70 million
P/E Ratio-1.08
Dividend YieldN/A
BetaN/A

About Eyegate Pharmaceuticals (NASDAQ:EYEG)

Eyegate Pharmaceuticals logoEyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:EYEG
CUSIPN/A
Phone+1-781-7889043

Debt

Debt-to-Equity Ratio0.01%
Current Ratio0.81%
Quick Ratio0.81%

Price-To-Earnings

Trailing P/E Ratio-1.07692307692308
Forward P/E Ratio-1.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$670,000.00
Price / Sales32.35
Cash FlowN/A
Price / CashN/A
Book Value($0.03) per share
Price / Book-42.00

Profitability

Trailing EPS($1.17)
Net Income$-13,340,000.00
Net Margins-2,480.28%
Return on Equity-1,494.75%
Return on Assets-100.47%

Miscellaneous

Employees11
Outstanding Shares17,200,000

Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

How were Eyegate Pharmaceuticals' earnings last quarter?

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) released its quarterly earnings data on Tuesday, November, 14th. The specialty pharmaceutical company reported ($0.24) EPS for the quarter, meeting the consensus estimate of ($0.24). Eyegate Pharmaceuticals had a negative net margin of 2,480.28% and a negative return on equity of 1,494.75%. View Eyegate Pharmaceuticals' Earnings History.

When will Eyegate Pharmaceuticals make its next earnings announcement?

Eyegate Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Eyegate Pharmaceuticals.

Where is Eyegate Pharmaceuticals' stock going? Where will Eyegate Pharmaceuticals' stock price be in 2018?

2 equities research analysts have issued 1-year target prices for Eyegate Pharmaceuticals' stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Eyegate Pharmaceuticals' share price to reach $5.00 in the next year. View Analyst Ratings for Eyegate Pharmaceuticals.

Who are some of Eyegate Pharmaceuticals' key competitors?

Who are Eyegate Pharmaceuticals' key executives?

Eyegate Pharmaceuticals' management team includes the folowing people:

  • Paul G. Chaney, Chairman of the Board (Age 59)
  • Stephen From, President, Director (Age 54)
  • Sarah M. Romano CPA, Chief Financial Officer, Corporate Controller
  • Lisa Brandano, Vice President - Clinical Operations
  • Michael Manzo, Vice President - Engineering (Age 57)
  • Carol Assang, Director - Clinical Operations
  • Mike Garanzini, Chief Commercial Officer
  • Barbara Wirostko M.D., Chief Medical Officer (Age 51)
  • Thomas Balland, Independent Director (Age 39)
  • Morton F. Goldberg, Independent Director (Age 79)

When did Eyegate Pharmaceuticals IPO?

(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

Who owns Eyegate Pharmaceuticals stock?

Eyegate Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include IPSA (INNOVEN PARTENAIRES S.A.) (7.20%). Company insiders that own Eyegate Pharmaceuticals stock include Morton Goldberg, Sarah Romano, Stephen From and Ventech Capital Ii. View Institutional Ownership Trends for Eyegate Pharmaceuticals.

How do I buy Eyegate Pharmaceuticals stock?

Shares of Eyegate Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eyegate Pharmaceuticals' stock price today?

One share of Eyegate Pharmaceuticals stock can currently be purchased for approximately $1.26.

How big of a company is Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals has a market capitalization of $21.70 million and generates $670,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,340,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe.

How can I contact Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals' mailing address is 271 Waverley Oaks Rd Ste 108, WALTHAM, MA 02452-8475, United States. The specialty pharmaceutical company can be reached via phone at +1-781-7889043.


MarketBeat Community Rating for Eyegate Pharmaceuticals (EYEG)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eyegate Pharmaceuticals (NASDAQ:EYEG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.00$7.33$7.33
Price Target Upside: 309.84% upside367.29% upside543.27% upside473.27% upside

Eyegate Pharmaceuticals (NASDAQ:EYEG) Consensus Price Target History

Price Target History for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Eyegate Pharmaceuticals (NASDAQ:EYEG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/19/2017HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
5/19/2017Noble FinancialReiterated RatingBuyLowView Rating Details
12/6/2016Chardan CapitalReiterated RatingBuy$6.00N/AView Rating Details
12/1/2016Rodman & RenshawReiterated RatingBuy$10.00N/AView Rating Details
6/28/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Eyegate Pharmaceuticals (NASDAQ:EYEG) Earnings History and Estimates Chart

Earnings by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Eyegate Pharmaceuticals (NASDAQ EYEG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018($0.24)N/AView Earnings Details
11/14/2017Q3 2017($0.24)($0.24)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.19)($0.28)ViewN/AView Earnings Details
5/8/20173/31/2017($0.39)($0.39)$0.22 million$0.19 millionViewN/AView Earnings Details
2/23/2017Q4 2016($0.44)($0.38)ViewN/AView Earnings Details
11/1/2016Q3 2016($0.46)($0.36)ViewN/AView Earnings Details
8/10/2016Q2 2016($0.31)($0.46)$0.24 millionViewN/AView Earnings Details
5/13/2016Q1 2016($0.25)($0.31)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.20)($0.24)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.19)ViewN/AView Earnings Details
8/12/2015Q2 2015($0.24)ViewN/AView Earnings Details
5/15/2015Q1 2015($3.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Eyegate Pharmaceuticals (NASDAQ:EYEG) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.01 EPS
Next Year EPS Consensus Estimate: $-0.67 EPS

Dividends

Dividend History for Eyegate Pharmaceuticals (NASDAQ:EYEG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Eyegate Pharmaceuticals (NASDAQ EYEG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.60%
Institutional Ownership Percentage: 11.95%
Insider Trades by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Institutional Ownership by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Eyegate Pharmaceuticals (NASDAQ EYEG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/15/2017Sarah RomanoCFOBuy10,000$1.00$10,000.0032,500View SEC Filing  
8/10/2017Stephen FromInsiderBuy12,500$1.03$12,875.00272,465View SEC Filing  
3/6/2017Morton GoldbergDirectorSell8,919$3.00$26,757.009,441View SEC Filing  
9/15/2016Stephen FromInsiderBuy15,000$1.49$22,350.00139,965View SEC Filing  
6/15/2016Morton GoldbergDirectorSell15,000$3.16$47,400.0017,277View SEC Filing  
6/10/2016Ventech Capital IiMajor ShareholderSell28,600$3.04$86,944.001,608,973View SEC Filing  
6/8/2016Ventech Capital IiMajor ShareholderSell29,400$3.25$95,550.001,641,540View SEC Filing  
6/7/2016Morton GoldbergDirectorSell10,939$3.31$36,208.0943,216View SEC Filing  
2/19/2015(Innoven Partenaires S.A. IpsaMajor ShareholderBuy366,667$6.00$2,200,002.00View SEC Filing  
2/19/2015Paul G ChaneyDirectorBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eyegate Pharmaceuticals (NASDAQ EYEG) News Headlines

Source:
DateHeadline
Eyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO PositionEyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position
www.streetinsider.com - January 4 at 5:25 PM
Eyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position - StreetInsider.comEyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position - StreetInsider.com
www.streetinsider.com - January 4 at 9:23 AM
EyeGate Promotes Sarah Romano to Chief Financial OfficerEyeGate Promotes Sarah Romano to Chief Financial Officer
finance.yahoo.com - January 4 at 9:23 AM
With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry?With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry?
finance.yahoo.com - January 2 at 6:51 PM
ETFs with exposure to EyeGate Pharmaceuticals, Inc. : December 25, 2017ETFs with exposure to EyeGate Pharmaceuticals, Inc. : December 25, 2017
finance.yahoo.com - December 25 at 3:17 PM
Zacks: Brokerages Anticipate Eyegate Pharmaceuticals Inc (EYEG) Will Post Earnings of -$0.26 Per ShareZacks: Brokerages Anticipate Eyegate Pharmaceuticals Inc (EYEG) Will Post Earnings of -$0.26 Per Share
www.americanbankingnews.com - December 24 at 8:05 AM
EyeGate Awarded New US Patent for Iontophoretic Delivery of Corticosteroids to the Eye - GlobeNewswire (press release)EyeGate Awarded New US Patent for Iontophoretic Delivery of Corticosteroids to the Eye - GlobeNewswire (press release)
globenewswire.com - December 21 at 5:26 PM
Eyegate Pharma (EYEG) Reports New US Patent for Iontophoretic Delivery of Corticosteroids to the Eye - StreetInsider.comEyegate Pharma (EYEG) Reports New US Patent for Iontophoretic Delivery of Corticosteroids to the Eye - StreetInsider.com
www.streetinsider.com - December 20 at 9:26 AM
HC Wainwright Analysts Give Eyegate Pharmaceuticals (EYEG) a $5.00 Price TargetHC Wainwright Analysts Give Eyegate Pharmaceuticals (EYEG) a $5.00 Price Target
www.americanbankingnews.com - December 19 at 7:28 PM
EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the EyeEyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye
finance.yahoo.com - December 19 at 9:23 AM
Eyegate Pharma (EYEG) Achieves 75% Enrollment in Pivotal Phase ... - StreetInsider.comEyegate Pharma (EYEG) Achieves 75% Enrollment in Pivotal Phase ... - StreetInsider.com
www.streetinsider.com - December 18 at 5:25 PM
BRIEF-EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone PaymentBRIEF-EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment
www.reuters.com - December 18 at 9:37 AM
EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone PaymentEyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone Payment
finance.yahoo.com - December 18 at 9:37 AM
ETFs with exposure to EyeGate Pharmaceuticals, Inc. : December 12, 2017ETFs with exposure to EyeGate Pharmaceuticals, Inc. : December 12, 2017
finance.yahoo.com - December 12 at 5:53 PM
ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 30, 2017ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 5:26 PM
What Does Eyegate Pharmaceuticals Inc’s (EYEG) Share Price Indicate?What Does Eyegate Pharmaceuticals Inc’s (EYEG) Share Price Indicate?
finance.yahoo.com - November 30 at 9:51 AM
EyeGate Pharmaceuticals, Inc. :EYEG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017EyeGate Pharmaceuticals, Inc. :EYEG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 9:23 AM
FY2017 Earnings Forecast for Eyegate Pharmaceuticals, Inc. (EYEG) Issued By Zacks Investment ResearchFY2017 Earnings Forecast for Eyegate Pharmaceuticals, Inc. (EYEG) Issued By Zacks Investment Research
www.americanbankingnews.com - November 29 at 9:08 AM
Eyegate Pharmaceuticals (EYEG) and The Competition Head to Head AnalysisEyegate Pharmaceuticals (EYEG) and The Competition Head to Head Analysis
www.americanbankingnews.com - November 24 at 8:24 AM
Financial Contrast: Eyegate Pharmaceuticals (EYEG) versus Its CompetitorsFinancial Contrast: Eyegate Pharmaceuticals (EYEG) versus Its Competitors
www.americanbankingnews.com - November 21 at 1:34 PM
Contrasting Eyegate Pharmaceuticals (EYEG) & Its PeersContrasting Eyegate Pharmaceuticals (EYEG) & Its Peers
www.americanbankingnews.com - November 20 at 9:16 AM
Eyegate Pharmaceuticals (EYEG) "Buy" Rating Reiterated at HC WainwrightEyegate Pharmaceuticals' (EYEG) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - November 19 at 5:38 PM
ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 17, 2017ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 17, 2017
finance.yahoo.com - November 18 at 8:54 AM
Critical Survey: Eyegate Pharmaceuticals (EYEG) versus Its RivalsCritical Survey: Eyegate Pharmaceuticals (EYEG) versus Its Rivals
www.americanbankingnews.com - November 16 at 1:06 AM
Is Eyegate Pharmaceuticals Inc’s (EYEG) Liquidity As Good As Its Solvency?Is Eyegate Pharmaceuticals Inc’s (EYEG) Liquidity As Good As Its Solvency?
finance.yahoo.com - November 14 at 11:58 PM
BRIEF-Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year agoBRIEF-Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago
www.reuters.com - November 14 at 6:57 PM
EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business UpdateEyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 14 at 6:57 PM
GLOBAL OPHTHALMIC DRUGS MARKET FORECAST 2017-2025GLOBAL OPHTHALMIC DRUGS MARKET FORECAST 2017-2025
www.prnewswire.com - November 13 at 7:01 PM
BRIEF-EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgeryBRIEF-EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery
www.reuters.com - November 10 at 8:05 PM
Eyegate Pharma (EYEG) Reports Completion of Enrollment in ... - StreetInsider.comEyegate Pharma (EYEG) Reports Completion of Enrollment in ... - StreetInsider.com
www.streetinsider.com - November 9 at 2:44 AM
EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract SurgeryEyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery
finance.yahoo.com - November 9 at 2:44 AM
Eyegate Pharmaceuticals (EYEG) versus Teligent (TLGT) Head-To-Head SurveyEyegate Pharmaceuticals (EYEG) versus Teligent (TLGT) Head-To-Head Survey
www.americanbankingnews.com - November 4 at 1:20 AM
EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy - GlobeNewswire (press release)EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy - GlobeNewswire (press release)
globenewswire.com - November 3 at 7:02 PM
Eyegate Pharmaceuticals (EYEG) & Abbott Laboratories (ABT) Head-To-Head SurveyEyegate Pharmaceuticals (EYEG) & Abbott Laboratories (ABT) Head-To-Head Survey
www.americanbankingnews.com - November 3 at 5:12 PM
ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 2, 2017ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 7:44 PM
EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch StrategyEyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy
finance.yahoo.com - November 1 at 7:36 PM
Opko Health (OPK) versus Eyegate Pharmaceuticals (EYEG) Critical SurveyOpko Health (OPK) versus Eyegate Pharmaceuticals (EYEG) Critical Survey
www.americanbankingnews.com - October 31 at 1:06 PM
$180,000.00 in Sales Expected for Eyegate Pharmaceuticals, Inc. (EYEG) This Quarter$180,000.00 in Sales Expected for Eyegate Pharmaceuticals, Inc. (EYEG) This Quarter
www.americanbankingnews.com - October 31 at 12:38 PM
-$0.24 Earnings Per Share Expected for Eyegate Pharmaceuticals, Inc. (EYEG) This Quarter-$0.24 Earnings Per Share Expected for Eyegate Pharmaceuticals, Inc. (EYEG) This Quarter
www.americanbankingnews.com - October 29 at 3:32 AM
Financial Review: Eyegate Pharmaceuticals (EYEG) & Its CompetitorsFinancial Review: Eyegate Pharmaceuticals (EYEG) & Its Competitors
www.americanbankingnews.com - October 28 at 3:04 AM
Eye Care Thought Leaders Join EyeGate Scientific Advisory Board - GlobeNewswire (press release)Eye Care Thought Leaders Join EyeGate Scientific Advisory Board - GlobeNewswire (press release)
globenewswire.com - October 24 at 11:29 PM
Eyegate Pharmaceuticals, Inc. (EYEG) to Release Quarterly Earnings on TuesdayEyegate Pharmaceuticals, Inc. (EYEG) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 24 at 9:58 AM
Eye Care Thought Leaders Join EyeGate Scientific Advisory BoardEye Care Thought Leaders Join EyeGate Scientific Advisory Board
finance.yahoo.com - October 23 at 4:16 PM
ETFs with exposure to EyeGate Pharmaceuticals, Inc. : October 18, 2017ETFs with exposure to EyeGate Pharmaceuticals, Inc. : October 18, 2017
finance.yahoo.com - October 18 at 7:53 PM
Eyegate Pharmaceuticals, Inc. (EYEG) Short Interest UpdateEyegate Pharmaceuticals, Inc. (EYEG) Short Interest Update
www.americanbankingnews.com - October 14 at 2:04 AM
Head-To-Head Analysis: SCYNEXIS (SCYX) vs. Eyegate Pharmaceuticals (EYEG)Head-To-Head Analysis: SCYNEXIS (SCYX) vs. Eyegate Pharmaceuticals (EYEG)
www.americanbankingnews.com - October 1 at 12:18 PM
Eyegate Pharmaceuticals (EYEG) versus Astrazeneca PLC (AZN) Financial AnalysisEyegate Pharmaceuticals (EYEG) versus Astrazeneca PLC (AZN) Financial Analysis
www.americanbankingnews.com - September 27 at 6:22 AM
 Brokerages Anticipate Eyegate Pharmaceuticals, Inc. (EYEG) Will Announce Quarterly Sales of $180,000.00 Brokerages Anticipate Eyegate Pharmaceuticals, Inc. (EYEG) Will Announce Quarterly Sales of $180,000.00
www.americanbankingnews.com - September 23 at 1:40 PM
Form 8-K EYEGATE PHARMACEUTICALS For: Sep 12 - StreetInsider.comForm 8-K EYEGATE PHARMACEUTICALS For: Sep 12 - StreetInsider.com
www.streetinsider.com - September 13 at 12:27 AM
EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships - GlobeNewswire (press release)EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships - GlobeNewswire (press release)
globenewswire.com - September 12 at 12:12 AM

SEC Filings

Eyegate Pharmaceuticals (NASDAQ:EYEG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Eyegate Pharmaceuticals (NASDAQ EYEG) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.